Delayed warfarin induced skin necrosis in a patient with poor warfarin metabolizing activity due to interrupted warfarin therapy.
Tejasvita
T
Gaikwad
Kanjaksha
K
Ghosh
Shrimati
S
Shetty
D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D065729:Cytochrome P-450 CYP2C9; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D009336:Necrosis / Q000139:chemically induced / Q000235:genetics; D011110:Polymorphism, Genetic; D012867:Skin / Q000473:pathology*; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics
D000925:Anticoagulants; D014859:Warfarin; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases